Join Growin Stock Community!

Anebulo pharmaceuticals, inc.ANEB.US Overview

US StockHealthcare
(No presentation for ANEB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ANEB AI Insights

ANEB Overall Performance

ANEB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ANEB Recent Performance

-

Anebulo pharmaceuticals, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ANEB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ANEB Key Information

ANEB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ANEB Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Price of ANEB

ANEB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ANEB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.85
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.85
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ANEB's latest earnings report released?

    The most recent financial report for Anebulo pharmaceuticals, inc. (ANEB) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ANEB's short-term business performance and financial health. For the latest updates on ANEB's earnings releases, visit this page regularly.

  • How much cash does ANEB have?

    At the end of the period, Anebulo pharmaceuticals, inc. (ANEB) held Total Cash and Cash Equivalents of 9.04M, accounting for 0.96 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ANEB's EPS continuing to grow?

    According to the past four quarterly reports, Anebulo pharmaceuticals, inc. (ANEB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ANEB?

    Anebulo pharmaceuticals, inc. (ANEB)'s Free Cash Flow (FCF) for the period is -1.31M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.58% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ANEB?

    The latest valuation data shows Anebulo pharmaceuticals, inc. (ANEB) has a Price-To-Earnings (PE) ratio of -2.43 and a Price/Earnings-To-Growth (PEG) ratio of 0.72. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.